Samuel Denmeade, MD

About Samuel Denmeade, MD

Evaluation of Bindarit, a Novel Inhibitor of the CCL2 Chemokine Axis, as Therapy for Metastatic Prostate Cancer
Dr. Denmeade is testing a medication called Bindarit – an orally active compound already tested in over 500 patients. Bindarit affects a number of mediators of chemotherapy resistance, especially in bone. Preclinical studies will be performed to qualify Bindarit for testing in men with metastatic prostate cancer.

Potential patient benefit: Bindarit may represent a new and novel tumor microenvironment therapy for men with metastatic prostate cancer and holds the potential to improve the efficacy of chemotherapy.

Award

The Movember-PCF Creativity Award

Designation

Professor, Pharmacology & Molecular Sciences

University

The Johns Hopkins University School of Medicine